---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-23-000041"
form_type: "8-K/A"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2023-09-07T23:59:59+00:00"
generated_at: "2026-06-10T22:41:32.152731+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Travere completes asset sale to Mirum for up to $445M; pro forma shows reduced continuing ops revenue

## Summary
- Net cash proceeds of $210M at close plus up to $235M in milestones from sale of Chenodal/Cholbam to Mirum; estimated gain of $235M.
- Pro forma continuing ops revenue for H1 2023: $63M (down from $116.7M), net loss $198.6M, EPS ($2.75).
- Pro forma continuing ops revenue for FY2022: $109.5M (down from $212M), net loss $329.8M, EPS ($5.17).
- Pro forma balance sheet at June 30, 2023: cash $277M, total assets $897M, equity $348M.
- Milestone payments of up to $235M tied to annual net sales thresholds of $125M-$500M for divested products.

## SEC filing metadata
- accession: 0001438533-23-000041
- form_type: 8-K/A
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2023-09-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853323000041/0001438533-23-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853323000041/tvtx-20230831.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-23-000041
- JSON: https://secwatch.observer/filing/0001438533-23-000041.json
- Plain text: https://secwatch.observer/filing/0001438533-23-000041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.